-
Immuno-Oncology Symposium
June 11, 9:00 AM l Munich, Germany
This free event will focus on a number of key considerations for transitioning an immuno-oncology product from discovery to clinical trials, including:
Efficiency assessment in tumor models,
Manufacturing
Toxicology and safety evaluation
Clinical trial design
The final program will be available soon.
-
Citoxlab and Charles River Laboratories entered today into exclusive discussions
We are pleased to inform you that Charles River Laboratories International, Inc. (NYSE: CRL) and Citoxlab have entered today into exclusive discussions pursuant to an exclusivity agreement for the intended acquisition of Citoxlab by Charles River. The proposed transaction would be expected to close in the second quarter of 2019, subject to labor consultations and regulatory requirements.
-
Citoxlab California Symposia
Preliminary agenda now available! May 7th and May 9th 2019
This symposium will discuss regulatory strategies along with non-clinical case studies involving NCE and biologics. An opportunity to network with non-clinical experts and discuss toxicology, pharmacology and regulatory science.
-
Webinar – Extended One-Generation Reproductive Toxicity Study
Extended One-Generation Reproductive Toxicity Study – Webinar
Thanks to a solid expertise in Developmental and Reproductive Toxicology, Citoxlab has the experience and know-how required for managing such a complex study and has already built a robust Historical Control Dataset.
-
CNS Safety Pharmacology
Discover EEG as a powerful neurological readout with established translational applications:
Continuous video-EEG, electro-oculogram, electromyogram, telemetry in conscious models, seizure liability, etc.
-
Dermal drug and skincare products
25-years of dedicated experience
From preclinical to clinical phase III development: Wound healing efficacy models, early screening, skin sensitization, 3D skin models, etc.
\ Welcome
The Citoxlab Group offers a comprehensive range of pre-clinical services for pharmaceutical, biotechnology, chemicals, cosmetics, medical devices and food companies worldwide. Our scientists and regulatory experts provide customized advice to help your development projects progress in the most effective way.
The Citoxlab Group has more than
1300 employees working in France, Canada, Denmark, Hungary and USA.
Proximity, the latest technologies and easy access to scientists, make Citoxlab your one-stop CRO for pre-clinical research. We offer maximum flexibility and expertise, major factors that guarantee the quality of your non-clinical programs.
\ News
-
-
-
-
-
-
READ MORE
Webinar EOGRTS
Watch a replay of our webinar EOGRTS
An integrated evaluation of potential risks to development and reproduction is a key component in many marketing authorization applications.
Citoxlab offers developmental and reproductive toxicology (DART) studies accepted by worldwide regulatory authorities for the safety testing of pharmaceuticals, biologics, gene-therapy products, food additives, chemicals, agrochemicals, veterinary medicines and consumer products. Studies cover the whole scope of developmental and reproductive toxicology, testing for potential effects on fertility, through embryo‑fetal, post-natal and juvenile stages, up to the second generation.
Specialized evaluations can be combined in your DART studies, such as neurobehavioral testing, sperm/oestrous cycle analyses, developmental immunotoxicology, neuro-histomorphometry, skeletal development (X-ray, DXA, pQCT and microCT), genomics and extended one-generation reproductive toxicity study (EOGRTS).
By the way, since its adoption in 2011, the EOGRTS (OECD 443 test guideline) has become a key milestone in the assessment of potential effects of chemicals on fertility and development, including effects on the developing nervous and immune systems.
Thanks to a solid expertise in Developmental and Reproductive Toxicology, Citoxlab has the experience and know-how required for managing such a complex study and has already built a robust Historical Control Dataset.
In this Webinar, using experience gained during the conduct and reporting of EOGRTS, Citoxlab will present the lessons learned and discuss the development and benefits of conducting such a study, with special focus on the challenges faced both by registrants and CROs in meeting the volume of demand for those in the coming years.
Speakers and moderator experts
Judit Hargitai David Esdaile Glyn Horner Associate Scientific Director specialized in the scientific management of long-term studies Director of Science and Regulatory Affairs at Citoxlab Hungary Business Development Director 
